Updates are available Correction dated 2024-11-09
Click to view Correction: https://doi.org/10.1007/s00403-024-03459-2
-
Authors
Choe, James
Yan, Allison
Charrow, Alexandra
Mostaghimi, Arash
Shiboski, Stephen
Chang, Aileen Y.
Barbieri, John S.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR082918)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR078930)
- License Information
-
More Information
Article History
Received: 5 June 2024
Revised: 5 June 2024
Accepted: 26 June 2024
First Online: 11 July 2024
Change Date: 9 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00403-024-03459-2
Declarations
:
: Dr. Barbieri reported personal fees from Dexcel Pharma for consulting outside the submitted work. Dr. Mostaghimi has received consulting fees from Pfizer, hims, Digital Diagnostics, Concert, Lilly, and AbbVie as well as licensing/royalties from Pfizer and Concert and holds equity in and is on the advisory board for hims and Fig. 1. No other disclosures were reported.
: Not applicable.
: This study was approved by the Mass General Brigham (MGB) Institutional Review Board (2023P003578).
: John Barbieri.
: The National Institute of Arthritis and Musculoskeletal and Skin Diseases had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
